Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) antibody
|Synonyms||Flk1, Ly73, Flk-1, Krd-1, VEGFR2, VEGFR-2, sVEGFR-2, 6130401C07, FLK1, CD309, VEGFR, Vegfr-2, MGC93590, KDR, FLK-1, flk-1, vegfr-2|
Alternatives Flow Cytometry (FACS), Western Blotting (WB)
|4 references available|
|Quantity||0.1 ml (1 mg/ml) (Variants)|
|Price||Product not available in this region.|
|Alternative name||CD309 / VEGFR-2 / Flk-1|
|Immunogen||A synthetic peptide made to a C-terminal region of the murine VEGFR2 proteinsequence (between residues 1300-1367). [Swiss-Prot# P35918].|
|Description||Receptors for VEGF, VEGFB and PGF have a tyrosine-protein kinase activity. TheVEGF-kinase ligand/receptor signaling system plays a key role in vascular developmentand regulation of vascular permeability. VEGF and its high-affinity binding receptors, the tyrosine kinases FLK1 and FLT1, arethought to be important for the development of embryonic vasculature. It has beenshown that an alternately spliced form of FLT1 produces a soluble protein, termedsFLT1, which binds vascular endothelial growth factor with high affinity, playing aninhibitory role in angiogenesis. Alternate Names: anti-VEGFR-2 antibody, anti-VEGFR 2 antibody, anti-Protein-tyrosine kinase receptorflk-1 antibody, anti-Fetal liver kinase 1 antibody, anti-Kinase NYK antibody, anti-FLK1antibody, anti-KDR antibody, anti-Kinase insert domain receptor antibody, anti-KRD1antibody, anti-Ly73 antibody, anti-Protein tyrosine kinase receptor FLK1 antibody,anti-Vascular endothelial growth factor receptor 2 antibody.|
|Specificity||This antibody has only been shown to recognize the native form (180-190 kDa protein)of VEGFR-2, known as Flk-1 / KDR / VEGFR 2 (Vascular Endothelial Growth FactorReceptor 2), though it was raised against the precursor form. It has not beencharacterized against the other forms of VEGFR-2. It has not been tested forcross-reactivity with VEGFR-1. Species Reactivity: This antibody reacts with human protein. Other species have not yet been tested. Thisantibody has a high likelihood of also reacting with mouse and rat proteins. Localization: Type I membrane protein.|
|Application Notes||Suggested working dilutions: Western Blot 1 ug/ml|
|Purification||Aff - Purified|
|Buffer||Tris-citrate/phosphate buffer, pH 7-8. Preservative: 0.1% sodium azide|
|Storage||Store at 4C. Do not freeze.|
|Research Area||Cytokines, Receptors|
|Restrictions||For Research Use only|
|Detection of VEGFR2 doublet in CSF-IR/VEGFR2 chimera transfected lysate using ABIN250774. ECL 10 second exposure.|
Rahimi, Dayanir, Lashkari: "Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells." in: The Journal of biological chemistry, Vol. 275, Issue 22, pp. 16986-92, 2000 (PubMed).
Gluzman-Poltorak, Cohen, Shibuya et al.: "Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes." in: The Journal of biological chemistry, Vol. 276, Issue 22, pp. 18688-94, 2001 (PubMed).
Takahashi, Hattori, Iwamatsu et al.: "A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1." in: The Journal of biological chemistry, Vol. 279, Issue 44, pp. 46304-14, 2004 (PubMed).
Hu-Lowe, Zou, Grazzini et al.: "Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 14, Issue 22, pp. 7272-83, 2008 (PubMed).